Dermatitis Herpetiformis: Novel Perspectives by Antiga, Emiliano et al.
REVIEW
published: 11 June 2019
doi: 10.3389/fimmu.2019.01290
Frontiers in Immunology | www.frontiersin.org 1 June 2019 | Volume 10 | Article 1290
Edited by:
Takashi Hashimoto,
Osaka City University, Japan
Reviewed by:
Russell P. Hall,
Duke University, United States
Chika Ohata,
Kurume University School of
Medicine, Japan
*Correspondence:
Roberto Maglie
robertomaglie.med@libero.it
Marzia Caproni
marzia.caproni@unifi.it
†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Autoimmune and Autoinflammatory
Disorders,
a section of the journal
Frontiers in Immunology
Received: 01 March 2019
Accepted: 21 May 2019
Published: 11 June 2019
Citation:
Antiga E, Maglie R, Quintarelli L,
Verdelli A, Bonciani D, Bonciolini V
and Caproni M (2019) Dermatitis
Herpetiformis: Novel Perspectives.
Front. Immunol. 10:1290.
doi: 10.3389/fimmu.2019.01290
Dermatitis Herpetiformis: Novel
Perspectives
Emiliano Antiga †, Roberto Maglie*†, Lavinia Quintarelli, Alice Verdelli, Diletta Bonciani,
Veronica Bonciolini and Marzia Caproni*
Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
Dermatitis herpetiformis (DH) is an inflammatory disease of the skin, considered the
specific cutaneous manifestation of celiac disease (CD). Both DH and CD occur in
gluten-sensitive individuals, share the same Human Leukocyte Antigen (HLA) haplotypes
(DQ2 and DQ8), and improve following the administration of a gluten-free diet. Moreover,
almost all DH patients show typical CD alterations at the small bowel biopsy, ranging
from villous atrophy to augmented presence of intraepithelial lymphocytes, as well as the
generation of circulating autoantibodies against tissue transglutaminase (tTG). Clinically,
DH presents with polymorphic lesions, including papules, vesicles, and small blisters,
symmetrically distributed in typical anatomical sites including the extensor aspects of the
limbs, the elbows, the sacral regions, and the buttocks. Intense pruritus is almost the
rule. However, many atypical presentations of DH have also been reported. Moreover,
recent evidence suggested that DH is changing. Firstly, some studies reported a reduced
incidence of DH, probably due to early recognition of CD, so that there is not enough time
for DH to develop. Moreover, data from Japanese literature highlighted the absence of
intestinal involvement as well as of the typical serological markers of CD (i.e., anti-tTG
antibodies) in Japanese patients with DH. Similar cases may also occur in Caucasian
patients, complicating DH diagnosis. The latter relies on the combination of clinical,
histopathologic, and immunopathologic findings. Detecting granular IgA deposits at
the dermal-epidermal junction by direct immunofluorescence (DIF) from perilesional
skin represents the most specific diagnostic tool. Further, assessing serum titers of
autoantibodies against epidermal transglutaminase (eTG), the supposed autoantigen of
DH, may also serve as a clue for the diagnosis. However, a study from our group has
recently demonstrated that granular IgA deposits may also occur in celiac patients with
non-DH inflammatory skin diseases, raising questions about the effective role of eTG IgA
autoantibodies in DH and suggesting the need of revising diagnostic criteria, conceivably
emphasizing clinical aspects of the disease along with DIF. DH usually responds to the
gluten-free diet. Topical clobetasol ointment or dapsone may be also applied to favor
rapid disease control. Our review will focus on novel pathogenic insights, controversies,
and management aspects of DH.
Keywords: dermatitis herpetiformis, epidermal transglutaminase, coeliac disease, non-coeliac gluten sensitivity,
direct immunofluorescence
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INTRODUCTION
About 135 years ago, the American dermatologist Luis Duhring
reported for the first time an itching andmultiform skin eruption
with erythema, papules, bullae, pustules, and above all, grouped
vesicles localized at typical areas (1). At that time, he had seen
15 cases of such a disease, and he decided to name it “dermatitis
herpetiformis,” due to its clinical similarity to herpes virus
infection (1). After the identification of dermatitis herpetiformis,
several years passed before the second important step in its early
story until 1950, when dapsone was accidentally found to be
effective for the treatment of the disease (2). Then, 50 years ago,
Van der Meer described the typical IgA deposits at the papillary
tips, which represent the immunological hallmark of DH as well
as the clue for the diagnosis of the disease (3).
However, it was only in the 60s and, above all, in the 70s
that DH was clearly related to gluten intolerance, allowing to
consider the disease as the specific cutaneous manifestation
of celiac disease (CD). In fact, patients with DH were shown
to have in most cases intestinal changes similar to those
found in CD (4) and to share the same genetic background
of CD (5), and gluten-free diet (GFD) was demonstrated to
improve skin symptoms (6), although more slowly than the
gastrointestinal ones.
Since then, several issues about the pathogenesis and the
management of DH have been pointed out (7). Among them,
the identification of reliable serologic markers of the disease (8)
and the discovery of epidermal transglutaminase (eTG) as the
autoantigen of DH were some of the most remarkable steps (9).
DH can be defined as a disease presenting with: (i)
symmetrical polymorphic lesions involving typical areas such
as the extensor aspects of the limbs and sacral region, (ii) a
predominant neutrophilic infiltrate at the dermal papillae at
histopathology, (iii) granular IgA deposits along the dermal-
epidermal junction, (iv) an invariable association with CD, and
(v) a response to a lifelong GFD (7).
However, despite the growing knowledge about the disease,
several issues have to be clarified yet, and some of the
cornerstones of DH need further discussion. For example,
the specificity of IgA deposits in the perilesional skin of
patients with DH could be questioned and the diagnostic
algorithm should be revised (10), taking also into account
the identification of non-coeliac gluten sensitivity (NCGS)
as a new entity among the spectrum of gluten-related
disorders (11); moreover, the pathogenic role of IgA anti-
eTG antibodies needs further demonstration, since they may
also occur in patients without DH (12). Finally, even the
therapeutic role of GFD is discussed, since some authors
suggest that it can be interrupted in the (rare) case of DH
remission (13).
The current review will try to address or at least to
focus on these and other issues that are still under debate
in the context of DH. The picture that hopefully will come
out would be that of a lively disease that represents both a
pathogenic model of autoimmunity and a paradigmatic example
of how the skin can be the mirror of an internal condition
such as CD.
THE EPIDEMIOLOGY OF DERMATITIS
HERPETIFORMIS: A (RARE) DISEASE OF
THE WESTERN COUNTRIES
DH is a rare disease that occurs prevalently in Caucasian
individuals. In Europe and USA, the prevalence of DH ranges
from 11.2 to 75.3 per 100.000, with the highest reported in
Finland; whereas, the incidence ranges from 0.4 to 2.6 per 100.000
people per year (14–16). DH is extremely rare among African
and Asian populations. Reasons explaining the low prevalence
of DH among such populations include the absence of DH
predisposing human leukocyte haplotypes (HLA) DQ2 and DQ8,
which are always found in Caucasian DH patients, and the low
wheat consumption in these geographic areas (17). However,
in the Asians, including Chinese and Japanese populations, the
association between DH and CD seems to be weaker than in
Western countries, despite DH presents with similar clinical
and immunopathological features. The extreme rarity of CD
in these populations may have led, indeed, to overlook the
diagnosis of DH and possibly underestimate the prevalence of the
disease (17, 18).
During the last decades, the overall incidence of DH
is significantly decreased, although the incidence of CD is
increasing (19–22). One plausible explanation for the opposite
trends in the epidemiology of CD and DH could be the increased
awareness of CD among physicians and patients and the wide
prescription of CD screening tests even in patients without
typical gastrointestinal manifestations, leading to identify early
patients with latent or potential CD.
DH can occur at any age, but typically occurs during
adulthood, and mostly between the third and the fourth decade
of life (14). Interestingly, in one Finnish study including 477
patients diagnosed with DH over a 40 year period, the patients’
age at DH diagnosis was shown to significantly increase over
time. This is presumably related to a parallel decrease of the
annual consumption of wheat during the same period, leading
to a lower lifetime gluten load (16).
DH has been also reported to occur in pediatric patients, but
the exact incidence of DH during childhood is unknown. In one
study by our group in 2013 including 159 DH patients, about
36% were diagnosed below the age of 20 (23). Other authors
have suggested a possible underestimation of pediatric DH due
to clinical overlapping features with atopic dermatitis, which
still accounts for the most prevalent dermatologic disease among
children (24). Unlike CD, DH seems to occur most commonly in
man, although the male/female ratio has reportedly ranging from
2:1 to 1:1 according to different studies (16, 19, 24). Interestingly,
a Finnish study found that in females there is a longer diagnostic
delay compared to male (25).
Associated Diseases
Like CD, DH has been found to be associated with several
autoimmune disorders, including type I diabetes mellitus,
autoimmune thyroid diseases, and connective tissue diseases,
such as Sjögren syndrome (24). Of interest is also the reported
association between DH and bullous pemphigoid (BP), a
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subepidermal autoimmune blistering disease characterized by
autoimmunity against the hemidesmosomal antigens BP180 and
BP230 (26, 27). Accordingly, in a retrospective case-control
study, diagnosis of DH was found to increase of 22 folds the risk
of BP, compared to only a 2-fold higher risk of developing BP
amongst coeliac patients. The mean time between the diagnosis
of DH and BP development was about 3 years (27).
Since virtually all patients with DH have CD, DH patients
also carry an increased risk of non-Hodgkin lymphomas
and gastrointestinal malignancies (28). However, unlike CD,
mortality of DHpatients is not increased (29–31). Accordingly, in
a large population-based study including 476 patients with DH,
a reduced mortality for all the causes of death compared to the
general population and a significantly reduced mortality related
to cerebrovascular diseases were shown. Mortality due to non-
Hodgkin lymphomas was increased only during the first 5 years
following the diagnosis but not thereafter. DH patients were also
found to have less hypercholesterolemia, and there were fewer
smoker compared to the control population (32). Ali and Lear
speculated that smoking might have a protective effect against
DH, since it suppresses natural killer (NK) lymphocytes and
reduces intestinal IgA secretion (33–36). Finally, an association
between DH and higher social class have been reported, and
may contribute to the observed reduced mortality reflecting the
“many facets of better living” of a high socioeconomic status (33).
Clinical Manifestations
The polymorphism and the symmetrical distribution of the
lesions represent the major clinical hallmarks of DH (37, 38).
The disease usually presents with grouped erythematous
papules and urticarial plaques with overwhelming vesicles. The
latter may then coalesce into small tense blisters with sero-
hemorrhagic content, which are characterized by a centrifugal
growth pattern. Erosions, excoriations, and crusts are likely to
occur because of blisters rupture and because of the scratching
secondary to the associated pruritus (15, 38, 39). Lesions
eventually heal leaving post-inflammatory hypo- and hyper-
pigmentation (Figures 1, 2).
Typically, DH lesions symmetrically localized at the extensor
surfaces of upper and lower limbs, mostly at the elbows and
knees, buttocks, and the sacral region; the abdomen, upper back,
shoulders, nuchal area, and the scalp may also be involved,
whereas the face and groin are rarely affected.
Likewise, mucosal involvement has sporadically been
reported. Oral manifestations of DH mainly consist of erosions
affecting both the oral mucosa and the tongue; associated
symptoms include pain and burning sensation (15, 40).
However, it is not clear whether oral involvement has to be
considered as a specific manifestation of DH or, rather, a sign of
the underlying CD; accordingly, oral aphthosis, erosions, and/or
ulcerations are also frequently found in CD (40–44).
Pruritus is the leading symptom of DH and its absence is a
strong argument against the diagnosis (45). In one study by our
group including a cohort of 159 patients, almost all complained of
severe pruritus, which had a significantly negative impact on the
patient’s quality of life. Moreover, in many cases, pruritus along
with a stinging and burning sensation of the skin was shown to be
FIGURE 1 | Clinical presentation of dermatitis herpetiformis (DH):
erythematous grouped papules and vesicles associated with excoriations and
crusts at the back (A), sacral region and buttocks (B). Rarely, DH may also
affect the groin and pubis (arrow) (C). The patient gave written informed
consent for the publication of these pictures.
FIGURE 2 | Clinical presentation of dermatitis herpetiformis: grouped papules
and vesicles associated with excoriations and crusts at the elbows (A) and
lower limbs (B). Post-inflammatory pigmentary changes such as
hypo-pigmentation could be also appreciated (B). The patient gave written
informed consent for the publication of these pictures.
the presenting sign of DH, preceding of 12–24 h the appearance
of the cutaneous lesions (46). Notably, pruritus has reportedly
occurred even months before the onset of skin lesions (47, 48).
Atypical Cases of Dermatitis Herpetiformis:
Are They Always Dermatitis Herpetiformis?
Several atypical cases of DH have been reported in the literature.
Asymptomatic palmoplantar petechiae, occurring either alone or
in association with characteristic DH clinical findings, have been
reported in some cases of pediatric DH. Petechiae were found
to occur prevalently at the dominant hand or foot, suggesting
repeated microtraumatism as a possible trigger (44, 49–55).
Moreover, Naylor et al. reported a case of DH presenting
with a diffuse petechial rush and microscopic changes consistent
with both DH and vasculitis (56). Kern et al. reported a
patient with DH presenting as pseudovasculitis, characterized
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by a diffuse petechial rush and a large ulcer at his extensor
forearm, and histopathologic and direct immunofluorescence
(DIF) findings consistent with DH without additional signs of
small-vessel inflammation (57). A possible hypothesis of the
association between DH and vascular damage might be the
presence of perivascular IgA immune complexes leading to small
vessel inflammation.
Finally, cases of DH presenting as palmoplantar keratosis
(58), purpuric lesions with chronic urticaria (59), and prurigo
pigmentosa-like lesions (60) have been also reported.
PATHOGENESIS
DH represents a paradigmatic model of autoimmune disease,
owing that it can be switched on or off by a known external
trigger: the gluten. The pathogenesis of DH, which relies
on a complex inflammatory network along the gut-skin axis,
remains at present only partly understood. Over the past 30
years, major efforts have led to the identification of eTG
as the main autoantigen of DH and to well-characterize
the inflammatory microenviroment underlying skin lesions
development. However, controversies still persist about the
mechanisms by which (i) anti-eTG autoantibodies develop, (ii)
they form the typical granular aggregates at the dermal papillary
tips, and (iii) eventually induce the appearance of the skin
lesions. Herein, we summarized the current knowledge of DH
pathogenesis, highlighting the major controversial issues that
may represent the starting point for future researches (Figure 3).
HLA DQ2/DQ8 and Gluten Are Required for
the Occurrence of Dermatitis Herpetiformis
About 5–10% of DH patients have a first-degree relative affected
by either DH or CD (61–63), suggesting that genetic factors
play a major pathogenic role in the disease. Previous studies
have found an association between DH and both HLA class
I and II molecules, including HLA A1, B8, DR3, and DPB1
(64). However, the closest association occurs with HLA-DQ2
(combination of the DQA1∗0501 and DQB1∗02 alleles) and DQ8
(combination of the DQA1∗03 and DQB1∗0302 alleles), which
can be found in roughly 85 and 15% of the patients, respectively
(65). Other studies have tried to investigate the role of more
than 40 other non-HLA gene polymorphisms in the pathogenesis
of both CD and DH, but none has yielded convincing
results (66–69).
Both HLA-DQ2 and DQ8, whose genes map on the
chromosome 6, are crucially involved in processing the gluten
antigen gliadin (70), corresponding to the same predisposing
haplotypes found in coeliac patients (71, 72). In CD, tissue TG
(tTG) catalyze deamidation of gliadin, creating epitopes that
increase gluten-peptide binding affinity to HLA-DQ2 and DQ8
expressed on the surface of antigen presenting cells, leading to
an adaptive immune reaction against both tTG and gliadin. In
parallel, activation of innate immunity leads to characteristic
small bowel alterations, including reversible villous atrophy in
the upper part of the jejunum, crypt hyperplasia on small bowel
mucosal samples and prominent intraepithelial lymphocytosis
(73–75). Virtually all DH patients show evidence of a potential
or manifest, usually mild, CD, suggesting that DH represents
a specific cutaneous manifestation of CD (76). The pathogenic
relevance of HLA-DQ and gluten intake in DH has been
further demonstrated experimentally by Marietta and coworkers.
Firstly, they observed that, unlike other autoimmune blistering
dermatoses, passive transfer of DH serum into athymic mice
with human skin engrafts did not induce DH lesions. However,
DH lesions developed in about 17% of HLA-DQ8 positive
autoimmune prone NODmice when they were exposed to gluten
through periodic intraperitoneal injections. This suggests that
DH develops only in the presence of predisposing HLA-DQ
antigens together with gluten exposure (77, 78).
An exception to what aforementioned is DH occurring in
Japanese populations. To date, only two studies have delineated
the clinical and immunological features of Japanese DH,
including a total of 116 patients, suggesting the extreme rarity
of DH in Japan. Although these studies were biased by the
fact that the results of some analyzed parameters, including
the presence of villous atrophy, circulating antibodies, and
response to a GFD, were available only for a few patients,
some peculiar characteristics of Japanese DH have emerged,
including (i) the absence of HLA DQ2/DQ8 haplotypes, (ii) the
absence of an underlying CD, (iii) a higher clinical involvement
of non-predilection sites such as the extremities and trunk,
(iv) fibrillar rather than granular IgA deposits in the papillary
dermis of a substantial proportion of patients, and (v) a lower
incidence of CD-associated autoimmune diseases and non-
Hodgkin lymphomas (Table 1) (18, 79). Even in some Chinese
DH patients, the disease was shown to occur outside the setting
of CD, which is also very rare in China (80). Altogether, these
observations raise speculation on the existence of a subgroup of
DH that may be not elicited by gluten, although showing some
clinic-pathologic features like in gluten-related DH.
Triggers Other Than Gluten Possibly
Involved in the Pathogenesis of Dermatitis
Herpetiformis
There is evidence that external triggers other than gluten may
induce or worsen DH. For example, potassium iodide, a common
compound of expectorants, has reportedly been a trigger of
DH both after oral ingestion and when applied topically (81).
Similarly, Snider et al. described two cases of DH elicited by a
cleaning solution (82).
Kovaleski et al. reported on two cases of DH following
a gastric stapling procedure and a gastrectomy with partial
pancreatectomy and colectomy, respectively (83). Similarly,
a non-coeliac patient developing DH after a mini-gastric
bypass surgery was reported (84). In these cases, the authors
hypothesized that the surgery-induced enteral inflammation
promoted a cross-reaction between cutaneous and intestinal
anti-TG antibodies, that seems to be in accordance with the
recent demonstration of the intestinal origin of anti-eTG IgA
autoantibodies (85).
Hormonal factors, and specifically the hypothalamic-
pituitary-gonadal axis, may play a role in DH. Accordingly,
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FIGURE 3 | Pathogenesis of dermatitis herpetiformis (DH): Production of IgA autoantibodies against eTG occurs in the gut, probably as a result of an epitope
spreading phenomenon (1), due to the high sequence homology between tissue TG, which is a major autoantigen in coeliac disease, and eTG. Activation of innate
immunity in the gut leads to increased release of IL-8, which is thought to be responsible for the initial priming of neutrophils (2). One theory suggests that, in region of
trauma, keratinocyte damage leads to shedding of eTG to the dermal-epidermal junction (3), where it binds to anti-eTG IgA. An alternative hypothesis suggests that
eTG/IgA complexes exists as circulating immune complexes, which can deposit both at the dermal-epidermal junction and around dermal vessels (4). A complex
interplay between inflammatory cytokines and the activation of fibrinogen stimulate neutrophil adherence to the activated endothelium (5) and migration to the dermal
papillae. Herein neutrophils, which probably bind to IgA aggregates through the Fc IgA receptor, release proteases, which finally induce the cleavage of the
dermal-epidermal junction (6). In parallel, hyper-activation of Th2 cells activate eosinophils, which also co-operate with neutrophils to the cleavage of the
dermal-epidermal junction. Down-regulation of Treg cells do also occur, favoring the maintenance of a pro-inflammatory microenvironment in DH skin. Abbreviations in
the figure: eTG, epidermal transglutaminase; tTG, tissue transglutaminase; IL, interleukin; Th, T helper cell; Treg, regulatory T cell; APC, antigen presenting cell.
hormone replacement therapy for panhypopituitarism has been
reported to cure DH (86). One study reported DH following
progesterone contraception (87). Other two studies reported DH
occurrence after a therapy with leuprolide acetate, an analog of
the gonadotropin-releasing hormone (GnRH). In both cases,
lesions resolved upon drug discontinuation. However, in one
case, skin lesions recurred once the patient was started on
biculatamide, another GnRH analog (88, 89).
Intriguingly, drugs may be also a potential trigger of DH.
Marakli et al. described a patient who developed DH while on
therapy with the Tumor Necrosis Factor-alfa inhibitor infliximab
for an ankylosing spondylitis (90); whereas, Mochel et al. recently
illustrated a patient who developed DH after several weeks of
ipilimumab treatment for a metastatic melanoma. Interestingly,
the patient had a positive result of anti tTG IgA antibodies
prior to the diagnosis of the metastatic cancer but neither a
confirmed diagnosis of coeliac disease nor active skin rush before
taking ipilimumab (91). The latter is a monoclonal antibody
targeting CTLA-4 and is thought to exert its anti-tumor activity
by promoting T-cell activation and down-regulation of Treg
function (92). It is arguable that the reported patient had a latent
or silent gluten-sensitive enteropathy with an immunological
reaction against tTG and eTG, and that inhibition of Tregs
precipitated the manifestation of DH, in agreement with the
critical role of Treg in the disease pathogenesis (93).
Finally, DH has reportedly been occurred close to a diagnosis
of an adenocarcinoma of the lung and an autoimmune
pancreatitis in two Japanese patients, who had neither serum IgA
antibodies against eTG nor signs of an underlying CD (94).
Interestingly, a gastrointestinal infection appears to be an
essential factor for the induction of CD. Several pathogenes
have been suggested to trigger CD, including rotavirus, Epstein
Bar Virus, Cytomegalovirus, HCV, HBV, Bacteroides species,
C. jejuni, Pneumococcus, M. tuberculosis, and H. pylori (95).
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TABLE 1 | Different characteristics between Caucasian and Japanese patients with dermatitis herpetiformis.
Characteristics Caucasian DH Japanese DH
HLA HLA-DQ2 (DQB1*02:01)−85%
HLA-DQ8 (DQB1*03:02)−15%
HLA-DQ2 (DQB1*02:01)−0%
HLA-DQ8 (DQB1*03:02)−37%*
Sites of involvement Elbow, buttock, knee, face, ear, neck, scalp, groin Elbow, buttock, knee, face, ear, neck, scalp, groin
Non-predilection sites, including the extremities and trunk.
Whole body
Villous atrophy Most of the patients Not known**
Circulating anti-tTG IgA 50–95% 38%
Circulating anti-eTG IgA 50–95% 43%
DIF Granular IgA deposits Granular and fibrillar IgA deposits
Response to the GFD Most of the patients Lack of consistent data
Association with autoimmune
diseases
Frequent Rare
HLA, Human Leucocyte Antigen; DIF, Direct Immunofluorescent; GFD, gluten-free diet.
*The frequency of HLA-DQ8 refers to the study by Ohata et al. (18), where the allele was found in six (37%) out of 16 Japanese patients with DH (19).
**Found in three out of six patients in the study by Ohata et al. (79), including a total of 91 patients in 2012.
A recent study demonstrated a link between Reovirus, an
avirulent pathogen that elicit protective immunity, and the loss
of peripheral tolerance against dietary antigens, resulting in a
Th1-type immunity to dietary antigens. Moreover, the study
found an increased titer of antibodies against Reovirus in patients
with active CD and elevated serum anti-tTG autoantibodies,
suggesting a direct link between the pathogen and the induction
of CD (96). Whether there might be an infectious trigger also for
DH is far less clear (97).
To conclude, complex endocrine and immunologic factors
seem to play a role in modulating the inflammatory response in
DH, suggesting that its pathogenesis is much more complex than
a simple interaction between HLA-DQ antigens and gluten.
Epidermal Transglutaminase Is the Main
Autoantigen of Dermatitis Herpetiformis
Epidermal transglutaminase (eTG) belongs to a nine-member
Ca2+-dependent enzyme family that promotes the formation of
covalent cross-links between proteins (98). eTG is physiologically
expressed in the spinous layer of the epidermis, and contribute to
epidermal terminal differentiation, formation of the cornified cell
envelop, and protection of keratinocytes against UVB-induced
apoptosis (99–102).
While tTG was shown to be a major autoantigen of CD,
Sardy et al. identified eTG as the main autoantigen of DH
(9). Specifically, they observed that CD and DH patients had
autoantibodies targeting both tTG and eTG; however, IgA
autoantibodies binding selectively and with high avidity to eTG
were found only in DH patients. Moreover, eTG, but not tTG,
was found to co-localize with IgA in the granular deposits at
the papillary tips of DH skin (9). The mechanism by which
both CD and DH patients develop an autoimmune response
against eTG remains still obscure. One suggested hypothesis is
related to epitope spreading (99). The phenomenon of epitope
spreading involves the development over time of a humoral or
cell-mediated immune response from an initial dominant epitope
to a secondary one, belonging to the same (intramolecular) or
a distinct (intermolecular) antigen (103). Evidence supporting
the theory of epitope spreading in DH include: (i) the high
sequence homology between tTG and eTG (9); (ii) the presence
of an autoimmunity also against neuronal TG (or TG6), which
is also highly similar to tTG and eTG, in both CD and DH
(99); (iii) the lower prevalence of anti-eTG IgA autoantibodies
in pediatric compared to adult CD patients, which (iv) parallels
the decreased, albeit not abolished, incidence of DH during
childhood (23, 104).
One recent study demonstrated that patients with active DH
secreted considerably high amounts of anti-eTG IgA in the
organ culture medium of small bowel mucosal biopsies, and had
eTG-binding IgA-positive cells in the lamina propria, thereby
suggesting that autoimmunity against eTG possibly develops in
the gut (85). Interestingly, small bowel secretion of eTG-targeting
IgA did not occur in CD patients, despite they showed elevated
levels of such autoantibodies in the serum (85).
An unmet issue concerns the mechanism underlying the
formation of eTG/IgA aggregates in the skin. One theory suggests
that, in regions of trauma, where DH lesions classically occurs,
epidermal damage leads to eTG shedding from the spinous layer
to the upper dermis, where it binds to circulating anti-eTG
IgA. A study by Zone et al. supports this hypothesis, showing
that passive transfer of goat anti-eTG IgG or DH serum into
mice with human skin grafts reproduced DH-like deposits only
in the engrafted skin, the only source of human eTG (105).
An alternative hypothesis is that eTG/IgA aggregates exists
as circulating immune complexes. Accordingly, DH patients
may show asymptomatic IgA immune complex deposition in
the kidney (106); Preisz et al. described deposits of eTG/IgA1
complexes in both upper and deep dermal vessels in roughly
64% of DH patients (107); rare clinical manifestations of DH
include digital purpura and ecchymosis, that show evidence
of small vessels vasculitis on microscopic examination (49,
108); circulating eTG/IgA immune complexes can be found in
patients with DH and their concentrations decrease under the
GFD (109).
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TABLE 2 | Evidence which seem to support or point against the pathogenic
relevance of eTG/IgA deposits which are typically found in the perilesional skin of
patients with DH.
Evidence supporting the pathogenic role of eTG/IgA aggregates in
DH
1) Circulating eTG IgA correlate with disease activity and disappear after a
GFD
2) eTG/IgA complexes are enzimatically active, and activate fibrinogen at the
tips of the papillary dermis
3) Circulating and skin resident neutrophils express Fc IgA receptor (CD89),
suggesting a direct interaction between neutrophils and IgA.
Evidence against the pathogenic role of eTG/IgA aggregates in DH
1) eTG/IgA complexes can be found in the healthy skin of patients with DH
2) eTG/IgA complexes can be detected in the skin of coealic patients without
DH
3) eTG/IgA complexes disappears even years after the introduction of the
GFD and the resolution of the skin rash
4) Passive transfer of goat anti-eTG IgG or human DH sera in mice with
human skin grafts reproduces DH-like granular deposits in the engrafted
skin, but not DH lesions
DH, dermatitis herpetiformis; eTG, epidermal transglutaminase; IgA, immunoglobulin A;
GFD, gluten free diet.
Pathogenic Relevance of IgA
Autoantibodies Against Epidermal
Transglutaminase
A major controversial issue concerns the role of eTG/IgA
aggregates in DH, since some studies clearly support their
pathogenic relevance, whilst others did not (Table 2). For
example, serum anti-eTG IgA autoantibodies has proven to
correlate positively with disease activity (110): along with anti-
tTG IgA and anti-endomysium autoantibodies (EmA), they
significantly decrease in patients achieving clinical remission
owing to the GFD, while increasing in patients who suffer
a relapse (111). However, passive transfer of goat anti-eTG
autoantibodies or DH human serum into SCIDmice with human
skin grafts fails to induce DH lesions, despite the formation of
the typical granular eTG/IgA deposits into the engrafted skin
(105, 112).
In the skin, eTG/IgA aggregates have been shown to activate
fibrinogen, which can be found at the tips of the papillary
dermis in a pattern similar to that of eTG/IgA aggregates
(113). Fibrinolysis directly contributes to the blister formation
in DH, and it is also believed to function as a chemoattractant
for neutrophis, T-cells and macrophages, which are major
components of the inflammatory infiltrate of DH (114). Both
circulating and skin resident neutrophils in DH have been
shown to highly express Fc IgA receptors, suggesting activation
dependent on the interaction with the eTG/IgA complexes (115,
116). However, Donaldson et al. observed that granular IgA
deposits could be also detected in the non-affected skin of DH
patients (114). More intriguingly, Cannistraci et al. documented
eTG/IgA co-localization in the papillary dermis, at the dermal-
epidermal junction and in the vessel walls of coeliac patients
without skin manifestations both before and during a GFD
(10, 117, 118). It is also worth of mention that disappearance
of eTG/IgA deposits from the skin occurs only in a subset of
patients despite a long and strict GFD and no active skin rash,
and takes much longer than serum autoantibodies or immune
complexes (76, 119).
Recently, Taylor and Zone found that Potassium Iodide,
a known precipitating factor of DH, increases the capacity
of eTG/IgA complexes to bind the substrate cadaverin in
normal skin cryosections from DH patients on dapsone or
on a GFD. Thus, one could speculate that, during disease
remission, eTG/IgA complexes preserve a baseline enzymatic
activity, allowing tight binding with anchoring fibrils of the BMZ
but not the activation of fibrinogen (76, 120).
Cytokine Network in Dermatitis
Herpetiformis and Mechanisms of Blister
Formation
The mechanisms leading to tissue damage in DH are only partly
understood. Themicroscopic finding of neutrophil accumulation
at the papillary dermis and the responsiveness of skin lesions to
dapsone support the key role of neutrophils in DH inflammation.
Circulating neutrophils in DH show an increased expression of
CD11b, decreased cell surface L-selectin, and increased Fc IgA
receptor function, suggesting that they have already been primed
before migrating into the skin (115). Indeed, neutrophils priming
is likely to occur in the gut under the influx of gut-derived IL-
8 (121). Accordingly, IL-8 mRNA was shown to be significantly
increased in the small bowel of DH patients on a normal
diet compared to that on a GFD. Circulating IL-8 decreases
following the GFD, while persists elevated in DH patients who
take a normal diet. A positive correlation between serum IL-
8 and anti-tTG IgA antibodies has been also demonstrated,
suggesting that the cytokine levels parallel the ongoing mucosal
inflammation in the gut and depend directly on gluten ingestion
(121). Likewise, the underlying mucosal inflammation leads
to enhanced expression of the adhesion molecule E-selectin
in endothelial cells from both lesional and non-lesional skin
(122). Local production of cytokines and chemokines, including
IL-8 and GM-CSF, in the presence of eTG/IgA deposits
eventually allow migration of adhered neutrophils to the
papillary dermis (121, 123). A recent study demonstrated a down-
regulation of elafin, a serine protease inhibitor that inhibits a
neutrophil mediated inflammatory response, in keratinocytes
from DH skin. A similar finding could be also found in the
epithelial cells from the small bowel of patients with active
CD (124).
Activated neutrophils release neutrophil elastase and
granzyme B, which induce subepidermal split by cleaving
adhesion molecules of the BMZ, such as collagen VII (125).
Accordingly, immunomapping studies have shown that dermal-
epidermal detachment in DH mainly occurs within the lamina
lucida, between collagen VII and laminin 332, and probably
involves destruction of laminin 332 (126, 127). In addition,
basal keratinocytes over-expresses collagenase, stromelysin-1,
and urokinase-type plasminogen activator, which contribute to
degrading basement membrane zone proteins (128).
The activation of the coagulation cascade is thought to be
an additional pathomechanism of DH. Accordingly, Bognar
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et al. found a high prevalence of criofibrinogenaemia in
untreated DH patients (129). Another study demonstrated an
impaired fibrinogen/fibrin turnover in the disease.More in detail,
untreated DH patients showed significantly prolonged clot lysis
time and thicker fibrin fibers, which could be normalized by
the in vitro adjunct of dapsone (130). Conversely, unlike BP,
no studies demonstrated significant skin expression of tissue
factor as well as elevation of serum D-dimer in patients with DH
compared to healthy individuals (131, 132).
Previous studies have also suggested that other inflammatory
cells participate to the pathogenesis of DH (133). In particular, T-
lymphocytes, mononuclear phagocytes and B-cells were shown
to accumulate around dermal vessels during the early phases of
DH lesion formation (134). Other studies found increased Th2-
related cytokines in the skin but not in the serum of DH patients
(133, 135). By comparison, Makino et al. recently reported a
significant elevation of IL-4, IL-5, IL-13, and eotaxin in fibrillary-
type DH, whereas Th1-related cytokines, including IL-12 and
IFN-γ, did not show significant differences compared to healthy
controls (136).
In another study, our group demonstrated that, in DH skin,
Tregs and IL-10 were significantly reduced compared to the skin
of healthy subjects, whereas both coeliac and DH patients had
a similar number of Tregs in duodenal biopsies, suggesting that
the down-regulation of Tregs in the skin may be critical for the
development of DH lesions (93).
The Pathogenesis of Pruritus in Dermatitis
Herpetiformis
While over the recent years different studies have gradually
shed light on the major pathogenic mechanisms of DH, the
pathogenesis of pruritus is far less clear. Probably, different
pathways are involved, including neurogenic inflammation,
mechanical itch dysesthesias, and release of inflammatory
cytokines. Accordingly, Cynkier et al. demonstrated an over-
expression of neuropeptides, including corticotropin releasing
factor and the receptor for endotelin B in DH lesional skin, which
may be released by activated keratinocytes (137). In DH, pruritus
may be evoked or worsened by mechanical stimuli (allokinesis),
such as clothing.Moreover, the intensity of the perceived pruritus
is also enhanced (hyperkinesis).
Among inflammatory cytokines involved in pruritogenesis,
IL-31 has gained a major interest. IL-31 belongs to the cytokine
family of IL-6. IL-31 interacts with a heterodimeric receptor,
which comprises the IL-31 receptor A (IL-31RA) and the
oncostatin M receptor (138), and is expressed on various
immune cells including T cells, keratinocytes, dendritic cells,
eosinophils, basophils, macrophages, and dorsal root ganglia
(139–145). In mice, over-expression of IL-31 was shown to
evoke pruritus and induce inflammatory cells accumulation with
increased number of mast cells. Injection of IL-31 in the dog also
triggers a scratching behavior. Several studies have demonstrated
an over-expression of IL-31 in the skin of different pruritic
dermatoses, including atopic dermatitis (146), psoriasis (147),
cutaneous T-cell lymphomas (148), nephrogenic pruritus (149),
and mastocytosis (145).
IL-31 seems to be particularly implicated in pruritic
dermatoses related to a prevalent Th2 type inflammation (150). A
recent study demonstrated that eosinophils are the major source
of IL-31 in BP, a prototype of highly pruritic Th2-mediated
autoimmune blistering dermatoses (151). We have previously
shown that Th2 type cytokines are also elevated in the skin
of DH patients, thereby allowing speculation about a possible
role of IL-31 in the associated pruritus. Interestingly, while a
previous paper did not show significant elevation of serum IL-31
concentration in DH patients (152), a recent study by our group
demonstrated that IL-31 was not only elevated in DH serum, but
also significantly over-expressed in the skin, where it co-localized
with IL-31RA (153).
Intriguingly, a monoclonal antibody targeting IL-31 is
currently under clinical investigation in atopic dermatitis (154).
If the role of IL-31 in DH pruritus were to be confirmed,
IL-31 monoclonal antibodies will open interesting therapeutic
perspectives, potentially allowing a faster control of DH pruritus,
which is typically refractory to either topical or systemic
treatments and improve only after months following a GFD.
GLUTEN AND THE SKIN: NOT ALWAYS
DERMATITIS HERPETIFORMIS
Although DH is the specific cutaneous manifestation of CD,
several other skin diseases secondary to gluten ingestion are
increasingly reported, especially in the last years, when the focus
on gluten intolerance has grown steadily. In fact, despite the
exclusion of gluten from the diet is even becoming a fashion,
data from the literature demonstrate a higher incidence of skin
diseases in patients with gluten-related disorders (14).
In 2012, Sapone et al. reviewed the spectrum of gluten-
related disorders, including CD, DH, wheat allergy, gluten ataxia,
and non-celiac gluten sensitivity (NCGS) (155). In their review,
the authors highlighted that gluten ingestion could cause the
involvement of different organs (such as bowel, nervous system,
and skin), via the activation of different pathogenic mechanisms.
Accordingly, in recent years, several studies focused on skin
manifestations different from DH that occurred in patients with
both CD and NCGS.
The Skin in Celiac Patients
According to the classification proposed by Humbert et al. (156),
our group recently reviewed in detail the cutaneous and mucosal
manifestations associated with CD (43). As a result, different
groups of CD-related skin diseases were identified; however, the
main distinction was between those that improve after a GFD and
those that are just occasionally associated with CD.
In general, common dermatological diseases such as psoriasis,
atopic dermatitis, urticaria, aphtous stomatitis, and rosacea are
more frequently diagnosed in celiac patients than in the general
population (157). Notably, their diagnosis is often difficult
because of atypical clinical presentation, and their course is
sometimes characterized by the resistance to standard therapies
and the response (or at least the improvement) after the
introduction of a GFD.
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In this regard, the relationship between psoriasis and CD
has been studied in depth, and patients with psoriasis seem
to have a 3-fold increased risk of CD (158). Moreover, in a
recent meta-analysis, patients with psoriasis were demonstrated
to have an increased risk of positivity for serologic markers of
CD and GFD was suggested to be of potential benefit for celiac
antibody-positive patients with psoriasis (159).
Despite the association between the aforementioned skin
diseases, testing patients having psoriasis, atopic dermatitis, or
other dermatologic diseases for CD is not advisable, since the
relative risk is low. There are only few conditions in which the
screening is recommended, such as type 1 diabetes mellitus,
autoimmune thyroiditis, autoimmune liver disease, juvenile
chronic arthritis, Down syndrome, Turner syndrome, Williams
syndrome, IgA deficiency, as well as patients having first-degree
relatives with CD (160); among them, no skin disorders have been
included yet.
Non-celiac Gluten Sensitivity: The Skin as
a Major Target
NCGS is a new entity within the group of gluten-related disorders
that is being increasingly reported in the medical literature.
Despite the lack of specific biomarkers, that makes the diagnosis
of NCGS one of exclusion, the reported high frequency of the
disease and its potential impact on the quality of life make NCGS
a health challenge.
NCGS mainly affects the bowel; however, extra-intestinal
manifestations are common, being the skin one of the major
target of the disease.
To date, only two studies have investigated the cutaneous
manifestations of NCGS, including one by our group. In general,
skin lesions were found to be predominantly located on the
extensor surfaces of the upper and lower limbs, and consisted
of erythema, papules, crusts, and sometimes, vesicles, resembling
subacute eczema, or even DH. Some patients had hyperkeratotic
scales overlying mild erythematous plaques similar to psoriasis,
while others showed urticarial plaques or wheals (161, 162).
Besides the prevalent clinical phenotype, all the patients suffered
from intense pruritus, that in about 10% of the cases represented
the only symptom.
Interestingly, in both studies, patients were shown to respond
well to a GFD, with some patients achieving disease remission
within only 1 month following the GFD (161). It is worth
mentioning that about 80% of the patient included in our study
showed at DIF the presence of DH-like granular C3 deposits at
the dermal-epidermal junction, but none showed the presence
of IgA.
This immunopathologic profile, together with itching and the
resolution of the skin lesions after the introduction of a GFDwere
considered as the main features of this new entity, referred to as
“cutaneous gluten sensitivity.”
Despite the low number of enrolled patients, suggesting
that further studies are required to confirm these data, the
introduction of the concept of specific skinmanifestations related
to NCGS may be helpful for the management of the patients, as
is for DH and CD.
In fact, the main issue of NCGS is represented by the
diagnosis, that relies on a procedure that is impractical to be
implemented in the clinical setting (i.e., double blind placebo
controlled challenge with duodenal biopsy) (163). Accordingly,
the identification of specific skin features such as cutaneous
gluten sensitivity might allow the diagnosis of NCGS without the
need of invasive investigations.
DIAGNOSIS OF DERMATITIS
HERPETIFORMIS
DH is a difficult disease to be diagnosed. Accordingly, the delay
from the occurrence of the first symptoms or clinical signs to the
diagnosis is usually of several months or even years, although it
is reported to be decreasing in the last decades, probably due to a
major awareness both of DH itself and of coeliac disease (25).
This diagnostic delay is caused by the rarity of DH
and the polymorphic cutaneous manifestations, which can be
misdiagnosed as other chronic pruritic dermatoses including
autoimmune blistering diseases such as BP or Linear IgA bullous
dermatosis but also atopic dermatitis, eczema, prurigo, urticaria,
or scabies (7). Moreover, in the last years skin manifestations of
NCGS have emerged as a novel diagnostic challenge in patients
with gluten intolerance, since they can clinically resemble DH
and can share similar intestinal involvement (161, 162).
The Role of Skin Biopsy: Are IgA Deposits
Still Pathognomonic of Dermatitis
Herpetiformis?
After taking patient’s history and clinical examination, the
first step to make a diagnosis of DH is to perform a
skin biopsy. The biopsy specimen can be investigated for
histopathological examination, which may show typical features
such as subepidermal vesicles and blisters associated with
accumulation of neutrophils at the papillary tips (7). However, in
a third of the cases (164), histopathology is non-specific; atypical
findings have been also reported, including acantholysis, leading
to a possible histopathologic overlap with pemphigus (165).
Therefore, although histopathological examination may be
helpful, DIF from the perilesional skin is still considered the gold
standard for the diagnosis. The main finding is the presence of
granular IgA deposits at the dermal papillae and/or at the dermal-
epidermal junction (Figure 4) (7); in some cases, and in up to
50% of Japanese patients (79), a fibrillar deposition of IgA could
be found.
Besides IgA, other immunoreactants can be found at the
dermal-epidermal junction or at the dermal papillae in the
perilesional skin. Among them, IgG granular deposits are
infrequently detected, while IgM and C3 granular deposits are
present in more cases.
In some cases, patients may show only granular deposition of
C3 in the absence of IgA, IgG, or IgM. Recently, a case series
of 20 patients showing these findings at DIF has been reported
(166). Half of them had clinical features mimicking DH and
very few of them showed low titres of anti-eTG, anti-tTG, anti-
gliadin, and anti-BP180 antibodies. The authors proposed the
Frontiers in Immunology | www.frontiersin.org 9 June 2019 | Volume 10 | Article 1290
Antiga et al. Dermatitis Herpetiformis: Novel Perspectives
FIGURE 4 | Direct immunofluorescence of perilesional skin specimens from
patients with dermatitis herpetiformis (DH). Granular IgA deposits at the dermal
papillary tips are considered a pathognomonic finding of DH
(magnification 400×).
term granular C3 dermatosis to describe this condition (166),
that might be considered as an umbrella concept including
different diseases (DH, cutaneous gluten sensitivity, non-DH
dermatoses occurring in patients with CD) rather than a distinct
clinical entity.
Although its prominent role in the diagnostic algorithm for
DH, due to its high sensitivity and specificity, DIF can have
some limitations. As an example, several papers reported patients
diagnosed with DH according to compatible clinical features,
histopathology, concomitant presence of CD, the response to the
GFD or dapsone, and the recurrence of cutaneous lesions after a
gluten challenge, but showing negative DIF results (167, 168).
In some instances, DIF may result negative because of the
site of the biopsy; in fact, when the skin specimen is taken in
lesional skin or too far from the skin lesions, it may lack the
presence of IgA deposits (7). However, in some confirmed DH
cases, even repeated biopsies performed at different times gave
negative DIF results, suggesting that false-negative patients are
possible (169, 170).
Another pitfall can be related to the interpretation of DIF.
On this point, a recent paper from our group reported a
case-series of six celiac patients presenting with skin diseases
different from DH, such as contact eczema, dermatophytosis,
granuloma annulare, pytiriasis rosea, lichenoid dermatitis, and
psoriasis. Notably, all these patients showed a granular deposit
of IgA at the dermal-epidermal junction and/or at the papillary
tips (10). As previously mentioned, Cannistraci et al. observed
granular IgA deposits in the healthy skin of nine celiac patients
without any cutaneous manifestation (117). Both these studies
raise the hypothesis that granular IgA deposits may occur also
as a cutaneous marker of CD. Interestingly, while in study
by Cannistraci et al. coeliac patients showed IgA/eTG co-
localization in the granular deposits, no IgA/eTG co-localization
was documented in any case from our study.
To conclude, the diagnosis of DH should be the result
of an overall assessment, including clinical, histological, and
immunopathological findings and could not rely only on DIF
findings. Whether assessing the co-localization between IgA
and eTG deposits in the perilesional skin might be helpful
to confirm the diagnosis of DH in doubtful cases warrants
further investigation.
Beyond Direct Immunofluorescence:
Serology and Other Investigations
Among other examinations that can help in the diagnosis of DH,
serology plays a primary role, mainly as a screening tool. In fact,
as happens for CD, patients with DH test positive in the majority
of cases for anti-tTG, anti-EMA and anti-deamidated synthetic
gliadin-derived peptides, that overall showed a sensitivity ranging
from 50 to 95%, and a specificity higher than 90% (171).
Moreover, in the last years, after the demonstration of eTG as the
main autoantigen for DH, anti-eTG antibodies have been shown
to be a promising tool for the diagnosis of DH (12, 104, 111).
Unfortunately, although their sensitivity and specificity for DH
are close to those of anti-tTG antibodies, anti-eTG antibodies can
be found in about 30 to 50% of the patients with CD (12, 172), and
therefore, are not helpful to differentiate between DH and other
dermatoses occurring in celiac patients.
Other antibodies have been tested in patients with DH
showing promising results, such as anti-neo epitope tissue TG
(173) and anti-GAF3X antibodies (174); however they were no
further tested and their high sensitivity and specificity values
should be confirmed.
A comprehensive assessment of patients with DH can include
other investigations that may be helpful in doubtful cases.
Duodenal biopsy is usually not required but, since it is the
gold standard for the diagnosis of CD, it should be performed
if the clinical picture or other findings are highly evocative
for the diagnosis of DH but DIF results negative (7). In
that case, the presence of villous atrophy at histopathology is
important to confirm (or to exclude) the diagnosis of CD and
to support the introduction of a GFD, at least in the Caucasians.
Accordingly, it is worth noting that duodenal biopsy might be
not helpful in Japanese DH patients, because of the weaker
association of DH with CD in that population and because
diseases other than CD represent a more frequent cause of villous
atrophy in Asia, including tropical sprue, parasitic infections,
immunoproliferative small intestinal diseases and combined
variable immunodeficiency disease (175).
Since virtually all the patients with CD and DH, at least
in western countries, have HLA-DQ2 or DQ8 aplotypes, HLA
testing may be helpful for its high negative predictive value in
order to exclude a diagnosis of DH and to avoid repetition of
unnecessary investigations (171).
Finally, in the last years, other potential diagnostic tools have
been proposed for DH. As an example, dermoscopy was found
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to be helpful in the differential diagnosis of autoimmune bullous
diseases involving the scalp. In particular, patients with DH
usually show the absence of yellow scales, that are more typical
of pemphigus patients, but display extravasation and clustered
dotted vessels (176), that seem to be a specific finding of the
disease and are found even in the petechial lesions of palms and
soles (177).
Other more complex investigations, such as the analysis of
microbiota and of metabolic signature of the patients, may
provide some information on the patients with DH. However,
although they were investigated in detail in patients with CD,
paving the way for their potential use in the clinical setting
(178, 179), very scarce data are available for DH (180), and further
studies are needed to address the questions that are still open in
this field.
TREATMENT
The Central Role of Gluten: What’s Beyond
Gluten-Free Diet?
Since DH is the specific cutaneous manifestation of CD, at least
in the Caucasians, all the patients require a GFD. Although some
authors suggested that a subgroup of the patients with DH can
go into remission and, therefore, gluten-free diet may be stopped
(13), other studies demonstrated that DH is associated with
an increased risk of associated diseases, such as non-Hodgkin
lymphomas (28). Moreover, although this risk is higher in the
first 5 years after the diagnosis, it overlaps that of the general
population thereafter (32). As a result, since GFD in DH is a way
to prevent complications rather just a symptomatic treatment for
skin lesions, it should be maintained for all the life (181).
Gluten-free diet requires strict monitoring of all ingested
foods, it is time-consuming, and socially restricting (182),
and patient compliance depends on different individual and
environmental factors, with a self-reported diet adherence in
adult patients with CD ranging from 36 to 96%(183). By contrast,
patients with DH seem to have a better compliance to gluten-
free diet, with an overall adherence of 98% (percentage that
decreases to 72% for strict adherence) (32). However, since
gluten contamination is possible even in supposed gluten-
free food, nutritional monitoring, and participation in support
groups are recommended for both patients with CD and DH
(184). Moreover, some patients that adhere to gluten-free diet
are refractory even several years after the introduction of the
diet (185).
According to the limitations of gluten-free diet reported
above, novel approaches to treat patients with CD and DH
are currently under investigation. Such new therapies rely on
blocking at different steps the pathogenic process occurring in
gluten-sensitive disorders.
For example, the reduction of gluten immunogenicity via the
production of genetically modified grains may lead to a decrease
of the number of patients that are able to develop autoimmunity
to gliadin-tissue TG complexes (186). RNA interference is
another way that could be applied in order to reduce gluten
toxicity (187). Moreover, gluten exposure could be reduced using
some binders that allow its sequestration in the bowel lumen, or
by hydrolysis of gluten peptides that are resistant to proteolysis in
a physiological setting using orally administered glutenases (188).
Finally, the exposure to immunogenic peptides can be prevented
by altering gut permeability; in this regard, the blockade of
zonulin, a tight junction protein that regulates the epithelial
transit of molecules, with inhibitors such as larazotide has proven
to ameliorate symptoms of patients with CD (189).
Other steps that can be targeted in patients with CD are
related to the activation of the immune response. tTG activity
inhibition, HLA-DQ2 blocking with gluten peptide analogs or
immune tolerance induction using specific gluten epitopes are
under study or are being tested in patients with CD (190, 191).
Pharmacologic Treatment of DH: When
Gluten-Free Diet Is Not Enough
All the approaches reported above are being developed for
patients with CD but, since they are oriented to prevent gluten
sensitization or to restore gluten tolerance, they might work even
for DH. The latter, however, has some specific therapeutic issues
that differ from those of CD. In fact, while intestinal symptoms
usually resolve in few weeks, cutaneous manifestations may last
months or even years after the introduction of a GFD. Therefore,
in most cases, pharmacologic treatment is required in order to
control itching as well as the skin rash (7).
Despite the lack of randomized controlled trials, dapsone
has been considered the first line treatment in patients with
DH for over 70 years. Dosages of about 50 to 100mg per
day are usually sufficient to clear the skin rash. At these
dosages, side effects are usually rare. However, hemolytic
anemia and methemoglobinemia, that are dose-dependent side
effects, can be seen in some patients. As a result, all the
patients taking the drug should be followed up with frequent
testing of hemoglobin levels and reticulocytes. In patients with
glucose-6-posphate dehydrogenase deficiency dapsone treatment
is contraindicated (7).
In two case reports, topical dapsone 5% gel was also shown
to be effective as an adjuvant treatment for DH, which is
not adequately controlled by GFD or oral dapsone (192, 193).
Compared to the oral counterpart, topical dapsone shows a lower
incidence of side effects and can be administered safely in patients
with glucose-6-posphate dehydrogenase deficiency (192).
Possible alternatives to dapsone are the so-called
sulfonamides, including sulfasalazine, sulfapyridine, and
sulfamethoxypyridazine, that may potentially cause hemolytic
anemia and gastrointestinal upset, but require a less strict
monitoring than dapsone (7). Furthermore, a recent report
suggested that combination therapy with dapsone and
sulfasalazine may be effective in patients who do not tolerate
increasing doses of dapsone monotherapy (194).
Several other pharmacologic treatments have been proposed
for DH. Case reports do exist showing that cyclosporin A,
azathioprine, colchicine, heparin, tetracyclines, nicotinamide,
and mycophenolate may control the acute rash in patients
with DH (171). Among them, some authors suggested that
colchicine may be used as a second choice after dapsone, due
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to its antineutrophilic and antithrombotic activity (195), since
DH was reported to be associated with a decreased fibrinolytic
potential (130).
Besides these “old” drugs, biologics may become the next step
in DH pharmacologic treatment. Among them, rituximab has
been proven to be effective in a patient resistant to GFD, dapsone,
sulfasalazine, and conventional immunosuppressive agents such
as azathioprine, and was suggested as a viable treatment option
for recalcitrant DH (196).
Celiac Disease and Dermatitis
Herpetiformis: Is Prevention Possible?
In the last years, some authors focused on the risk factors
associated with the development of CD, aiming at the prevention
of the disease in genetically at-risk infants or children.
Randomized controlled trials investigated the possible role of
the age at which gluten is introduced, showing that neither
ingestion of small gluten amounts between weeks 16–24, nor
delayed introduction of gluten (at 6 or at 12 months) modified
the incidence of CD in the studied groups (197, 198).
Besides gluten, microbiota has been suggested to act as a
trigger in several autoimmune diseases, including CD. In the
latter, both genetic and environmental factors, such as rotavirus
infection, may modified the gut microbiota of at-risk patients
that, in turn, can affect bowel immunity and permeability (199).
In particular, altered gut microbiota increases the production of
pro-inflammatory cytokines, impairs the mucosal barrier, and
produces microbial TG (199), that is a target of antibodies found
in celiac patients (200). Therefore, targeting the gut microbiota
via probiotics may be a reasonable approach in order to prevent
CD in at-risk individuals, and trials are currently underway (199).
Notably, all these data are available for CD. However, due
to the close correlation with CD, it could be assumed that such
strategies may work even for the prevention of DH, and studies
on these topics would be advisable.
FINAL CONSIDERATIONS AND FUTURE
PERSPECTIVES
DH is an autoimmune bullous disease associated with a chronic,
usually asymptomatic, autoimmune enteropathy, that arises in
genetically susceptible individuals, in the presence of gluten
proteins consumed in common grain products.
One of the main concerns of DH is still represented by
misdiagnosis, due to its rarity, the growing report of atypical
clinical presentations and the possible occurrence of IgA deposits
in non-DH skin diseases. In the near future, the diagnostic
challenge is expected even to increase, due to the falling incidence
of DH (16). This is reflected by the quite long diagnostic delay,
found even in high prevalence areas (25).
In the last years, NCGS has emerged as a new entity
within the spectrum of gluten-related disorders. Similarities in
both clinical and immunopathological findings may enhance
the diagnostic challenge and have important therapeutic
implications. In fact, although GFD is the first line treatment
for both DH and NCGS, patients with DH should be followed
up closely for dietary adherence, nutritional deficiencies, and
potential complications.
Recent advances in the pathogenesis of DH have paved
the way for the development of new treatments to be used
in the time window between the beginning of the GFD
and the complete resolution of skin lesions. As an example,
the recent finding of elevated serum levels of IL-17 and
IL-36 in DH patients supported their possible role in the
activation of neutrophils and NK cells, making them as possible
targets for new therapeutic strategies (201). In addition, the
involvement of IL-31 pathway in DH suggests a connection
among the immune system, the nervous system and itch,
and its targeting holds promise for the treatment of the
patients (153).
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